With minimal (less than 0.5%) off‐target gene editing in high‐risk tissues, encapsulating nanocapsules demonstrated promising glioblastoma tissue targeting that resulted in up to 38.1% PLK1 gene editing efficiency in a brain tumor. The gene discussed is PLK1; the disease is brain neoplasm.